Celldex Therapeutics Stock Soars 7.5%, Hits Intraday High of $24.77

Celldex Therapeutics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable increase of 7.5% on November 11, 2025, reaching an intraday high of USD 24.77. This performance stands in contrast to the S&P 500, which recorded a modest gain of 1.54% on the same day.
Despite today's uptick, Celldex has faced challenges over the longer term. The company has reported a decline in net sales, with a significant drop of 46.31% in the first half of the year, and has experienced negative operating cash flow of USD -186.19 million. Over the past year, the stock has generated a return of -13.54%, reflecting ongoing struggles in profitability, as evidenced by a 35.1% decrease in profits.

Celldex's market capitalization is currently USD 1,554 million, and it operates with a negative return on equity of -30.46%. The stock's performance metrics indicate a consistent underperformance against the S&P 500 over the past three years, highlighting the challenges the company faces in a competitive market.